written on 23.04.2014
Tags:
,

NICE rejects Roche's hot new breast cancer drug Kadcyla, then invites negotiations

TAGS: ,

Let the price negotiations begin, the top executive for the U.K. price watchdog suggested today after the agency nixed Roche's pioneering breast cancer drug Kadcyla as too expensive.

Latest Report